The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Intermittent neutrophil recovery associated with improved CAR-T outcomes in R/R LBCL
Kai Rejeski, MD, LMU Munich, Munich, Germany, outlines the findings of a study exploring the impact of different neutrophil recovery phenotypes after CAR-T cell therapy on other toxicities and clinical outcomes of patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). In 344 patients, the biphasic/intermittent phenotype had the best survival outcomes. Additionally, when CAR-T cell expansion kinetics were evaluated by phenotype, the intermittent phenotype had more pronounced expansion and favorable expansion in relation to baseline tumor burden. This interview took place at the 64th ASH Annual Meeting and Exposition Congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
